metformin has been researched along with Squamous Cell Carcinoma of Head and Neck in 31 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors." | 5.37 | Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011) |
| "Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression." | 3.01 | Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma. ( Liu, J; Qiao, X; Zhao, J, 2023) |
| "Nondiabetic patients with LAHNSCC were enrolled in the current study to receive escalating doses of metformin and CRT based on the modified toxicity probability interval design." | 2.94 | Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer. ( Desai, J; Desai, PB; Gulati, S; Gutkind, JS; Jandarov, R; Mierzwa, M; Molinolo, A; Morris, JC; Palackdharry, SM; Riaz, MK; Sadraei, NH; Takiar, V; Wise-Draper, TM; Zhu, Z, 2020) |
| "Metformin was titrated to standard diabetic dose (2,000 mg/day) for a course of 9 or more days prior to surgery." | 2.84 | Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial. ( Birbe, R; Cognetti, D; Cotzia, P; Curry, J; Duddy, E; Gill, K; Johnson, J; Leiby, B; Lin, Z; Luginbuhl, A; Martinez-Outschoorn, U; Menezes, DW; Mollaee, M; Reyzer, M; Sprandio, J; Tassone, P; Tuluc, M; Vidal, MD; Zhan, T, 2017) |
| "Paired pre- and post-treatment primary HNSCC tumor samples were stained for CD8+ and FoxP3+." | 1.91 | CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition. ( Alnemri, A; Argiris, A; Curry, J; Fiorella, M; Harshyne, L; Johnson, J; Linnenbach, A; Luginbuhl, A; Martinez-Outschoorn, U; Philips, R; Solomides, C; South, A; Stapp, R; Sussman, S; Tuluc, M, 2023) |
| "Oral squamous cell carcinoma (OSCC) is considered as the sixth most common cancer worldwide characterized by high invasiveness, high metastasis rate and high mortality." | 1.91 | Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing. ( Chen, C; Ji, M; Li, X; Lv, Y; Ma, X; Qi, Y; Wang, Y; Xing, D; Xu, W; Zhang, J; Zhang, W; Zhao, J; Zhou, C, 2023) |
| "However, the role of IL-1RA in oral squamous cell carcinoma (OSCC), in particular the underlying mechanisms, remains to be elucidated." | 1.91 | IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway. ( Chan, LP; Chen, YK; Hu, SC; Hung, AC; Lo, S; Nguyen, HDH; Wang, YM; Wang, YY; Yuan, SF, 2023) |
| " Patients received platinum-based chemoradiation in combination with orally dosed metformin at one of 2 doses- 850 mg BID or 1500 mg BID administered during radiation, with a 2-week lead-in phase." | 1.91 | Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population. ( Chen, A; Chen, G; Florez, M; Hernandez, DJ; Hilsenbeck, SG; Jhaveri, P; Kemnade, JO; Miller-Chism, C; Sabichi, A; Sandulache, VC; Shaun, B; Skinner, HD; Zhang, J, 2023) |
| "Metformin is a potential anticancer drug." | 1.72 | Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma. ( Nie, HQ; Shao, SH; Su, T; Wang, WM; Yang, SS; Zhang, J, 2022) |
| "Metformin increased HNSCC NK cell cytotoxicity and inhibited the CXCL1 pathway while stimulating the STAT1 pathway within HNSCC NK cells." | 1.72 | Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. ( Borchers, M; Crago, A; Crist, M; Curry, J; Fuhrman, B; Gulati, S; Karivedu, V; Lehn, MA; Martinez-Outschoorn, U; Medvedovic, M; Palackdharry, S; Stone, T; Takiar, V; Wise-Draper, TM; Yaniv, B, 2022) |
| "Metformin is an antidiabetic drug that has been reported to have an inhibitory effect on different types of cancers, including oral squamous cell carcinoma (OSCC)." | 1.62 | Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells. ( Feng, X; Fu, X; Gu, W; Tian, H; Wang, Y; Wen, Y; Zhang, Y, 2021) |
| "Chemotherapy in head and neck squamous cell carcinoma (HNSCC) has many systemic side effects, as well as hypoxia-induced chemoresistance." | 1.56 | Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma. ( Cai, Y; Cheng, W; Han, W; Ran, J; Song, C; Tang, C; Wang, Y; Wei, Z; Xu, W; Zou, H, 2020) |
| "Treatment with metformin resulted in a dose-dependent induction of the stem cell genes CD44, BMI-1, OCT-4, and NANOG." | 1.51 | Metformin Results in Diametrically Opposed Effects by Targeting Non-Stem Cancer Cells but Protecting Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma. ( Abhold, E; Altuna, X; Honda, CO; Honda, TK; Kim, E; Kuo, SZ; Li, WT; Ongkeko, WM; Wang-Rodriguez, J, 2019) |
| "However, how TAMs interact with HNSCC cells to induce drug resistance, especially under hypoxic conditions, is unclear." | 1.51 | Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells. ( Cai, Y; Han, S; Han, W; Hu, Q; Ran, J; Song, C; Tang, C; Wang, Y; Wei, Z; Xu, W; Yin, X; Zou, H, 2019) |
| "Metformin may reduce the progression of head and neck squamous cell carcinoma (HNSCC); however, whether metformin acts by altering the host metabolism or targets cancer-initiating cells remains poorly understood." | 1.51 | Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells. ( Amornphimoltham, P; Ando, T; Chen, Q; Goto, Y; Gutkind, JS; Lippman, SM; Murphy, AN; Tamayo, P; Wang, Z; Wu, VH; Wu, X; Yeerna, H; Zhang, X, 2019) |
| "Both metformin and curcumin have been shown to display anticancer properties." | 1.51 | Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells. ( Biron, VL; Conrad, D; Harris, J; Kostiuk, M; Lindsay, C; O'Connell, DA; Seikaly, H, 2019) |
| "Metformin is an oral anti-hyperglycemic agent used to treat type 2 diabetes mellitus (DM)." | 1.46 | Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients. ( Blitzer, A; Lerner, MZ; Mor, N; Paek, H; Strome, M, 2017) |
| "Dasatinib is a Bcr-bl and Src kinase inhibitor that has potential against HNSCC." | 1.40 | Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress. ( Chen, CC; Huang, LY; Huang, WC; Lin, YC; Lin, YT; Wei, TT; Wu, MH, 2014) |
| "Metformin is a commonly utilized antidiabetic agent, which has been associated with improved clinical outcomes in cancer patients." | 1.40 | Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival. ( Sandulache, VC; Skinner, HD; Woo, SH; Yang, L, 2014) |
| "Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer in the world; the main risk factors are alcohol and tobacco use." | 1.38 | Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. ( Agarwal, C; Agarwal, R; Deep, G; Kaur, M; Sikka, A, 2012) |
| "A panel of 15 HNSCC cell lines was assayed for glucose and glutamine dependence and sensitivity to metabolic inhibitors." | 1.37 | Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. ( Davis-Malesevich, M; Fokt, I; Frederick, MJ; Myers, JN; Ow, TJ; Pickering, CR; Priebe, W; Sandulache, VC; Zhou, G, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 14 (45.16) | 24.3611 |
| 2020's | 17 (54.84) | 2.80 |
| Authors | Studies |
|---|---|
| Nguyen, MT | 1 |
| Choe, HC | 1 |
| Kim, BH | 1 |
| Ahn, SG | 1 |
| Wang, WM | 1 |
| Yang, SS | 1 |
| Shao, SH | 1 |
| Nie, HQ | 1 |
| Zhang, J | 5 |
| Su, T | 2 |
| Curry, J | 3 |
| Alnemri, A | 1 |
| Philips, R | 1 |
| Fiorella, M | 1 |
| Sussman, S | 1 |
| Stapp, R | 1 |
| Solomides, C | 1 |
| Harshyne, L | 1 |
| South, A | 1 |
| Luginbuhl, A | 2 |
| Tuluc, M | 2 |
| Martinez-Outschoorn, U | 3 |
| Argiris, A | 1 |
| Linnenbach, A | 1 |
| Johnson, J | 2 |
| Lin, YC | 3 |
| Chen, BS | 1 |
| Crist, M | 1 |
| Yaniv, B | 1 |
| Palackdharry, S | 1 |
| Lehn, MA | 1 |
| Medvedovic, M | 1 |
| Stone, T | 1 |
| Gulati, S | 2 |
| Karivedu, V | 1 |
| Borchers, M | 1 |
| Fuhrman, B | 1 |
| Crago, A | 1 |
| Takiar, V | 2 |
| Wise-Draper, TM | 2 |
| Ji, M | 2 |
| Lv, Y | 2 |
| Chen, C | 2 |
| Xing, D | 2 |
| Zhou, C | 2 |
| Zhao, J | 3 |
| Qi, Y | 2 |
| Wang, Y | 5 |
| Ma, X | 2 |
| Xu, W | 4 |
| Zhang, W | 2 |
| Li, X | 2 |
| Shanchun, H | 1 |
| You, P | 1 |
| Sujuan, N | 1 |
| Xuebing, Z | 1 |
| Yijie, B | 1 |
| Xiaohui, X | 1 |
| Jianming, H | 1 |
| La, N | 1 |
| Zhehui, B | 1 |
| Qi, L | 1 |
| Wulong, J | 1 |
| Yuan, SF | 1 |
| Wang, YM | 1 |
| Chan, LP | 1 |
| Hung, AC | 1 |
| Nguyen, HDH | 1 |
| Chen, YK | 1 |
| Hu, SC | 1 |
| Lo, S | 1 |
| Wang, YY | 1 |
| Kemnade, JO | 1 |
| Florez, M | 1 |
| Sabichi, A | 1 |
| Jhaveri, P | 1 |
| Chen, G | 1 |
| Chen, A | 1 |
| Miller-Chism, C | 1 |
| Shaun, B | 1 |
| Hilsenbeck, SG | 1 |
| Hernandez, DJ | 1 |
| Skinner, HD | 2 |
| Sandulache, VC | 3 |
| Liu, J | 1 |
| Qiao, X | 1 |
| Desai, J | 1 |
| Palackdharry, SM | 1 |
| Morris, JC | 1 |
| Zhu, Z | 1 |
| Jandarov, R | 1 |
| Riaz, MK | 1 |
| Mierzwa, M | 1 |
| Gutkind, JS | 2 |
| Molinolo, A | 1 |
| Desai, PB | 1 |
| Sadraei, NH | 1 |
| Song, C | 2 |
| Tang, C | 2 |
| Ran, J | 2 |
| Wei, Z | 2 |
| Zou, H | 2 |
| Cheng, W | 1 |
| Cai, Y | 2 |
| Han, W | 2 |
| Hu, Q | 2 |
| Peng, J | 1 |
| Jiang, L | 1 |
| Li, W | 1 |
| Su, Q | 1 |
| Li, H | 1 |
| Song, M | 1 |
| Cheng, B | 1 |
| Xia, J | 1 |
| Wu, T | 2 |
| Wei, J | 1 |
| Huang, J | 1 |
| Kuang, Y | 1 |
| Li, Y | 1 |
| Zhong, D | 1 |
| Song, J | 2 |
| Chen, H | 1 |
| Sa, G | 1 |
| Li, L | 1 |
| He, S | 1 |
| Zhang, Y | 1 |
| Feng, X | 1 |
| Tian, H | 1 |
| Fu, X | 1 |
| Gu, W | 1 |
| Wen, Y | 1 |
| Huang, DN | 1 |
| Chen, WX | 1 |
| Xiong, HF | 1 |
| Hu, X | 1 |
| Mao, T | 1 |
| Verma, A | 1 |
| Rich, LJ | 1 |
| Vincent-Chong, VK | 1 |
| Seshadri, M | 1 |
| Stokes, WA | 1 |
| Eguchi, M | 1 |
| Amini, A | 1 |
| Hararah, MK | 1 |
| Ding, D | 1 |
| McDermott, JD | 1 |
| Bradley, CJ | 1 |
| Karam, SD | 1 |
| Quimby, AE | 1 |
| Lebo, NL | 1 |
| Griffiths, R | 1 |
| Hall, S | 1 |
| Dimitroulakos, J | 1 |
| Johnson-Obaseki, S | 1 |
| Kuo, SZ | 1 |
| Honda, CO | 1 |
| Li, WT | 1 |
| Honda, TK | 1 |
| Kim, E | 1 |
| Altuna, X | 1 |
| Abhold, E | 1 |
| Wang-Rodriguez, J | 1 |
| Ongkeko, WM | 1 |
| Yin, X | 1 |
| Han, S | 1 |
| Wu, X | 1 |
| Yeerna, H | 1 |
| Goto, Y | 1 |
| Ando, T | 1 |
| Wu, VH | 1 |
| Zhang, X | 1 |
| Wang, Z | 1 |
| Amornphimoltham, P | 1 |
| Murphy, AN | 1 |
| Tamayo, P | 1 |
| Chen, Q | 1 |
| Lippman, SM | 1 |
| Lindsay, C | 1 |
| Kostiuk, M | 1 |
| Conrad, D | 1 |
| O'Connell, DA | 1 |
| Harris, J | 1 |
| Seikaly, H | 1 |
| Biron, VL | 1 |
| Wu, MH | 1 |
| Wei, TT | 1 |
| Huang, WC | 1 |
| Huang, LY | 1 |
| Lin, YT | 1 |
| Chen, CC | 1 |
| Woo, SH | 1 |
| Yang, L | 1 |
| Kwon, M | 1 |
| Roh, JL | 1 |
| Lee, SW | 1 |
| Kim, SB | 1 |
| Choi, SH | 1 |
| Nam, SY | 1 |
| Lerner, MZ | 1 |
| Mor, N | 1 |
| Paek, H | 1 |
| Blitzer, A | 1 |
| Strome, M | 1 |
| Tassone, P | 1 |
| Vidal, MD | 1 |
| Menezes, DW | 1 |
| Sprandio, J | 1 |
| Mollaee, M | 1 |
| Cotzia, P | 1 |
| Birbe, R | 1 |
| Lin, Z | 1 |
| Gill, K | 1 |
| Duddy, E | 1 |
| Zhan, T | 1 |
| Leiby, B | 1 |
| Reyzer, M | 1 |
| Cognetti, D | 1 |
| Ow, TJ | 1 |
| Pickering, CR | 1 |
| Frederick, MJ | 1 |
| Zhou, G | 1 |
| Fokt, I | 1 |
| Davis-Malesevich, M | 1 |
| Priebe, W | 1 |
| Myers, JN | 1 |
| Sikka, A | 1 |
| Kaur, M | 1 |
| Agarwal, C | 1 |
| Deep, G | 1 |
| Agarwal, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Window of Opportunity for Durvalumab (MEDI4736) Plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck[NCT03618654] | Phase 1 | 38 participants (Actual) | Interventional | 2018-11-01 | Active, not recruiting | ||
| Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.[NCT02083692] | Early Phase 1 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Phase I Dose-finding Study of Metformin in Combination With Concurrent Cisplatin and Radiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma[NCT02325401] | Phase 1 | 20 participants (Actual) | Interventional | 2015-05-11 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cohorts of patients received escalating doses of metformin (2000 mg, 2550 mg, or 3000 mg divided into daily doses) with a 7-day to 14-day lead-in prior to CRT based on the modified toxicity probability interval design to allow for possible re-escalation after previous de-escalation and to maximize the ability to identify the maximum tolerated dose (MTD). Patients continued to receive metformin for the duration of CRT as tolerated. (NCT02325401)
Timeframe: 24 months
| Intervention | mg (Number) |
|---|---|
| Metformin (2000mg) With Chemoradiation | NA |
| Metformin (2550mg) With Chemoradiation | NA |
| Metformin (3000mg) With Chemoradiation | NA |
Patients were evaulated at 36 months to determine if there was recurrence of disease. (NCT02325401)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 6 |
| Metformin (2550mg) With Chemoradiation | 8 |
| Metformin (3000mg) With Chemoradiation | 4 |
Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Adverse event means any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.Any participants with any adverse event at any grade was included. Adverse events were collected during the on study period of 21 weeks up to three months after the study for a total of 34 weeks. (NCT02325401)
Timeframe: 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 6 |
| Metformin (2550mg) With Chemoradiation | 7 |
| Metformin (3000mg) With Chemoradiation | 4 |
2 year overall survival (NCT02325401)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 5 |
| Metformin (2550mg) With Chemoradiation | 8 |
| Metformin (3000mg) With Chemoradiation | 4 |
2-year progression free survival (NCT02325401)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin (2000mg) With Chemoradiation | 6 |
| Metformin (2550mg) With Chemoradiation | 8 |
| Metformin (3000mg) With Chemoradiation | 4 |
1 review available for metformin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2023 |
Research Progress of Metformin in the Treatment of Oral Squamous Cell Carcinoma.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2023 |
2 trials available for metformin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Topics: Acute Kidney Injury; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
Phase 1 dose-finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer.
Topics: Acute Kidney Injury; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; M | 2017 |
Metformin effects on head and neck squamous carcinoma microenvironment: Window of opportunity trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Female; Head and Neck Neoplasms; Humans; M | 2017 |
28 other studies available for metformin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Guani | 2022 |
A new link between apoptosis induced by the metformin derivative HL156A and autophagy in oral squamous cell carcinoma.
Topics: Animals; Apoptosis; Autophagy; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Guani | 2022 |
Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Down-Regulation; ErbB Rece | 2022 |
Metformin Downregulates the Expression of Epidermal Growth Factor Receptor Independent of Lowering Blood Glucose in Oral Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Down-Regulation; ErbB Rece | 2022 |
CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
Topics: CD8-Positive T-Lymphocytes; Head and Neck Neoplasms; Humans; Lymphocytes, Tumor-Infiltrating; Metfor | 2023 |
CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
Topics: CD8-Positive T-Lymphocytes; Head and Neck Neoplasms; Humans; Lymphocytes, Tumor-Infiltrating; Metfor | 2023 |
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; | 2022 |
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications.
Topics: Biomarkers; Biomarkers, Tumor; Carcinoma, Squamous Cell; Deep Learning; Drug Design; Drug Discovery; | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
Topics: Carcinoma, Squamous Cell; Chemokine CXCL1; Cytokines; Head and Neck Neoplasms; Humans; Killer Cells, | 2022 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Metformin inhibits oral squamous cell carcinoma progression through regulating RNA alternative splicing.
Topics: Alternative Splicing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; | 2023 |
Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Gene Expression Regulation, Neoplastic; Head and Nec | 2023 |
Integrative analyses of biomarkers and pathways for metformin reversing cisplatin resistance in head and neck squamous cell carcinoma cells.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cisplatin; Gene Expression Regulation, Neoplastic; Head and Nec | 2023 |
IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; D | 2023 |
IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; D | 2023 |
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.
Topics: Head and Neck Neoplasms; Humans; Metformin; Prospective Studies; Retrospective Studies; Squamous Cel | 2023 |
Phase I / II trial of metformin as a chemo-radiosensitizer in a head and neck cancer patient population.
Topics: Head and Neck Neoplasms; Humans; Metformin; Prospective Studies; Retrospective Studies; Squamous Cel | 2023 |
Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chlorophyllides; Cisplati | 2020 |
Hypoxia-Targeting Multifunctional Nanoparticles for Sensitized Chemotherapy and Phototherapy in Head and Neck Squamous Cell Carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chlorophyllides; Cisplati | 2020 |
Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Metfor | 2020 |
Metformin as a senostatic drug enhances the anticancer efficacy of CDK4/6 inhibitor in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Metfor | 2020 |
Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2021 |
Metformin inhibits proliferation of oral squamous cell carcinoma cells by suppressing proteolysis of nerve growth factor receptor.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Head and Neck Neoplasms; Humans; Met | 2021 |
In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, T | 2021 |
In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, T | 2021 |
Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; H | 2021 |
Metformin inhibits mTOR and c-Myc by decreasing YAP protein expression in OSCC cells.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; H | 2021 |
[Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment].
Topics: Carcinoma, Squamous Cell; Humans; Male; Metformin; Mouth Neoplasms; Prognosis; Squamous Cell Carcino | 2021 |
[Preliminary clinical study on the effect of metformin on prognosis of patients with oral squamous cell carcinoma after surgical treatment].
Topics: Carcinoma, Squamous Cell; Humans; Male; Metformin; Mouth Neoplasms; Prognosis; Squamous Cell Carcino | 2021 |
Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Hemoglobins; | 2018 |
Visualizing the effects of metformin on tumor growth, vascularity, and metabolism in head and neck cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Proliferation; Female; Head and Neck Neoplasms; Hemoglobins; | 2018 |
Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Cohort Studies; Combined | 2018 |
Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Cohort Studies; Combined | 2018 |
Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study.
Topics: Aged; Aged, 80 and over; Comorbidity; Female; Humans; Hypoglycemic Agents; Male; Metformin; Retrospe | 2018 |
Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study.
Topics: Aged; Aged, 80 and over; Comorbidity; Female; Humans; Hypoglycemic Agents; Male; Metformin; Retrospe | 2018 |
Metformin Results in Diametrically Opposed Effects by Targeting Non-Stem Cancer Cells but Protecting Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma.
Topics: Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytoprotection; Elec | 2019 |
Metformin Results in Diametrically Opposed Effects by Targeting Non-Stem Cancer Cells but Protecting Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma.
Topics: Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytoprotection; Elec | 2019 |
Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Basic Helix-Loop-Helix Transcription Factors; Cell Communication; Ce | 2019 |
Metformin enhances gefitinib efficacy by interfering with interactions between tumor-associated macrophages and head and neck squamous cell carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Basic Helix-Loop-Helix Transcription Factors; Cell Communication; Ce | 2019 |
Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Elec | 2019 |
Metformin Inhibits Progression of Head and Neck Squamous Cell Carcinoma by Acting Directly on Carcinoma-Initiating Cells.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Elec | 2019 |
Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Gene Expression Regulation, Neoplastic; H | 2019 |
Antitumour effects of metformin and curcumin in human papillomavirus positive and negative head and neck cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Gene Expression Regulation, Neoplastic; H | 2019 |
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C | 2014 |
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C | 2014 |
Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cel | 2014 |
Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cel | 2014 |
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N | 2015 |
Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Diabetes Mellitus; Female; Head and Neck N | 2015 |
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human | 2017 |
Metformin Prevents the Progression of Dysplastic Mucosa of the Head and Neck to Carcinoma in Nondiabetic Patients.
Topics: Aged; Carcinoma, Squamous Cell; Disease Progression; Female; Glottis; Head and Neck Neoplasms; Human | 2017 |
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.
Topics: Adenosine Triphosphate; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Prol | 2011 |
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.
Topics: Adenosine Triphosphate; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Prol | 2011 |
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
Topics: beta-Transducin Repeat-Containing Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife | 2012 |
Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation.
Topics: beta-Transducin Repeat-Containing Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolife | 2012 |